111
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

The NOD/Shi-scid/IL-2Rγnull mice xenograft model recapitulates anaplastic large cell lymphoma dissemination to the bladder

, , , , , , , , , , , , & show all
Pages 1542-1543 | Received 16 Jul 2014, Accepted 11 Sep 2014, Published online: 24 Oct 2014

References

  • Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681–3695.
  • Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697–2706.
  • Pai SA, Naresh KN, Patil PU. Systemic anaplastic large cell lymphoma presenting as a bladder neoplasm. Leuk Lymphoma 2004;45:841–843.
  • Murphy AJ, O’Neill P, O’Brien F, et al. Anaplastic large cell lymphoma: a unique presentation with urinary bladder involvement: a case report. Int J Surg Pathol 2005;13:369–373.
  • Gómez-Román JJ, Cobo ML, Val-Bernal JF. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int 2008;58:249–252.
  • Blick C, Abdelhadi S, Bailey D, et al. Anaplastic, T-cell, non-Hodgkin's Lymphoma presenting with haematuria. Sci World J 2008;8:342–345.
  • Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010;28:3987–3993.
  • Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175–3182.
  • Pfeifer W, Levi E, Petrogiannis-Haliotis T, et al. A murine xenograft model for human CD30 + anaplastic large cell lymphomacell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 1999;155:1353–1359.
  • Zhang M, Yao Z, Zhang Z, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 2006;108:705–710.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.